Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5962712 | 0.86 | CHRM3 (0.39) | CHRM3POLBHTTTRPV1 | |
| SCHEMBL5966271 | 0.80 | SPHK2 (0.38) | CHRM3HTTTRPV1 | |
| SCHEMBL4408525 | 0.80 | ROCK2 (0.42) | CHRM3SMN1; SMN2ALDH1A1HTTMAPT | |
| SCHEMBL13594815 | 0.80 | ROCK2 (0.42) | CHRM3SMN1; SMN2ALDH1A1HTTMAPT | |
| SCHEMBL5962846 | 0.78 | EPHX2 (0.44) | CHRM3 | |
| SCHEMBL5962933 | 0.77 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1POLBPKMHTT | |
| SCHEMBL13594857 | 0.77 | KDM4E (0.47) | CHRM3SMN1; SMN2ALDH1A1PKMHTT | |
| SCHEMBL4409328 | 0.77 | KDM4E (0.47) | CHRM3SMN1; SMN2ALDH1A1PKMHTT | |
| SCHEMBL5963063 | 0.75 | LMNA (0.38) | CHRM3POLBRAB9AL3MBTL1TRPV1 | |
| SCHEMBL13594814 | 0.74 | CHRM3 (0.42) | CHRM3SMN1; SMN2ALDH1A1NPC1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067511-B2 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2006-06-27 | — | — | US | disclosed |
| US-7049311-B1 | Pyrrolbenzodiazepines | SPIROGEN LIMITED (GB) | 2006-05-23 | — | — | US | disclosed |
| EP-1109812-B1 | PYRROLOBENZODIAZEPINES | SPIROGEN LTD (GB) | 2005-05-04 | — | — | EP | disclosed |
| EP-1413582-A1 | Dimeric pyrrolobenzodiazepines | Spirogen Limited (GB) | 2004-04-28 | — | — | EP | disclosed |
| US-20030120069-A1 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2003-06-26 | — | — | US | disclosed |
| EP-1193270-A2 | Pyrrolobenzodiazepines | Spirogen Limited (GB) | 2002-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030120069-A1 | Pyrrolobenzodiazepines | CNR1, CBX2, CNR2 | CHRM3 99/4885SMN1; SMN2 2936/4885ALDH1A1 4469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.